{"classes":[{"categories":[{"measurements":[{"comment":"Median and upper limit of 95% CI could not be estimated due to low number of participants with events.","groupId":"OG000","lowerLimit":"7.39","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"}],"units":"Participants"}],"description":"PFS defined as the time from the date of the initial infusion of cilta-cel OOS to the date of first documented disease progression as per IMWG criteria, or death due to any cause, whichever occurs first. PD: increase of 25% from lowest response value: serum and urine M-component (absolute increase must be \\>=0.5 g/dL and \\>=200 mg/24 hours, respectively); only in participants without measurable serum and/or urine M-protein levels the difference between involved and uninvolved FLC levels (absolute increase must be \\>10 mg/dL); only in participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow PC percentage (absolute increase must be \\>=10%), appearance of a new lesion; definite development of new bone lesions or definite increase in the size of existing bone lesions, \\>=50% increase in circulating PCs (minimum of 200 cells per uL) if this was the only measure of disease.","dispersionType":"95% Confidence Interval","groups":[{"description":"Adult participants aged 18 years or older, with multiple myeloma received the lymphodepleting chemotherapy (cyclophosphamide 300 milligrams per meter square \\[mg/m\\^2\\] intravenous \\[IV\\] infusion and fludarabine 30 mg/m\\^2 IV infusion daily, for 3 days \\[Day -7 to Day -5\\]). After 5 to 7 days of initiating lymphodepleting chemotherapy, participants received IV infusion of cilta-cel OOS at a total targeted dose of 0.75\\*10\\^6 chimeric antigen receptor (CAR)-positive viable T-cells/kg (dose range 0.5\\*10\\^6 CAR-positive viable T cells/kg to 1.0\\*10\\^6 CAR-positive viable T cells/kg) based on participant's body weight at apheresis or per exceptional release criteria determined alternative dose.","id":"OG000","title":"Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS)"}],"paramType":"MEDIAN","populationDescription":"The all treated analysis set included all participants who received study intervention (cilta-cel OOS).","reportingStatus":"POSTED","timeFrame":"From Day 1 (post infusion) up to 18.6 months","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}